Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07925268
PHASE2

Study of Ifinatamab Deruxtecan in De Novo or Treatment-Emergent Neuroendocrine Prostate Cancer

Sponsor: Rahul Aggarwal

View on ClinicalTrials.gov

Summary

This is a Phase 2, open-label, single-arm study evaluating the safety and effectiveness of ifinatamab deruxtecan (I-DXd) in adult men with histologic evidence of de novo or treatment-emergent neuroendocrine prostate cancer (NEPC). I-DXd is an investigational antibody-drug conjugate (ADC) designed to target B7-H3, a protein found at high levels on many neuroendocrine prostate cancer cells. After binding to B7-H3, I-DXd delivers an anticancer drug called deruxtecan (DXd) to tumor cells. DXd interferes with an enzyme called topoisomerase I, which is involved in DNA replication and repair. This causes DNA damage that can lead to cancer cell death.

Official title: A Multi-center Phase 2 Study of Ifinatamab Deruxtecan in De Novo or Treatment-Emergent Neuroendocrine Prostate Cancer

Key Details

Gender

MALE

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

30

Start Date

2026-11-07

Completion Date

2031-11-30

Last Updated

2026-11-09

Healthy Volunteers

No

Interventions

DRUG

Ifinatamab Deruxtecan

Given intravenously (IV)

PROCEDURE

Positron Emission Tomography (PET)/Computerized Tomography (CT)

Undergo Imaging

PROCEDURE

Computerized Tomography (CT)/ Magnetic Resonance Imaging (MRI)

Undergo Imaging

PROCEDURE

Bone Scan

Undergo Imaging

PROCEDURE

Blood Specimen Collection

Perform blood draw

Locations (1)

University of California, San Francisco

San Francisco, California, United States